Fox Run Management L.L.C. Takes $327,000 Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Fox Run Management L.L.C. bought a new stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 3,989 shares of the company's stock, valued at approximately $327,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. KLP Kapitalforvaltning AS purchased a new position in shares of Vaxcyte during the fourth quarter worth about $1,842,000. American Century Companies Inc. grew its stake in Vaxcyte by 14.4% during the 4th quarter. American Century Companies Inc. now owns 605,267 shares of the company's stock worth $49,547,000 after buying an additional 76,262 shares during the last quarter. Teacher Retirement System of Texas grew its stake in Vaxcyte by 42.1% during the 4th quarter. Teacher Retirement System of Texas now owns 32,963 shares of the company's stock worth $2,698,000 after buying an additional 9,769 shares during the last quarter. Xponance Inc. increased its position in Vaxcyte by 13.4% during the fourth quarter. Xponance Inc. now owns 8,905 shares of the company's stock worth $729,000 after buying an additional 1,052 shares during the period. Finally, Cibc World Markets Corp purchased a new stake in Vaxcyte in the fourth quarter valued at approximately $951,000. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Teri Loxam sold 6,250 shares of the firm's stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total value of $531,937.50. Following the completion of the sale, the director now owns 7,175 shares in the company, valued at $610,664.25. This trade represents a 46.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Jim Wassil sold 8,000 shares of the business's stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $83.66, for a total transaction of $669,280.00. Following the sale, the chief operating officer now directly owns 205,695 shares in the company, valued at approximately $17,208,443.70. This represents a 3.74 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 46,250 shares of company stock valued at $3,840,018 in the last three months. 3.10% of the stock is currently owned by company insiders.

Remove Ads

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on PCVX shares. The Goldman Sachs Group began coverage on shares of Vaxcyte in a research report on Friday, December 20th. They set a "buy" rating and a $135.00 target price on the stock. Guggenheim reissued a "buy" rating and set a $160.00 price objective on shares of Vaxcyte in a research report on Wednesday, March 12th. Finally, Needham & Company LLC restated a "buy" rating and issued a $140.00 price objective on shares of Vaxcyte in a research note on Wednesday, February 26th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Vaxcyte presently has an average rating of "Buy" and an average price target of $147.50.

Vaxcyte Price Performance

Shares of PCVX stock traded down $1.31 during mid-day trading on Friday, hitting $69.46. The stock had a trading volume of 660,934 shares, compared to its average volume of 980,702. The firm has a market cap of $8.94 billion, a PE ratio of -15.10 and a beta of 1.02. The company's 50-day simple moving average is $80.07 and its 200-day simple moving average is $92.37. Vaxcyte, Inc. has a fifty-two week low of $58.10 and a fifty-two week high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, beating analysts' consensus estimates of ($1.16) by $0.14. On average, analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.